SGLT2 in Patients With Type 2 Diabetes Lowers Risk of Gout

A retrospective, adjusted analysis of people in China with type 2 diabetes significantly linked SGLT2 inhibitor use with a lower risk of gout compared with those receiving a DPP4 inhibitor.
First Look

source https://www.medscape.com/viewarticle/968066?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

New AAFP practice guideline sets blood pressure targets for adults with hypertension

Heart Failure Care Outside of ICU Can Lower Cost